NMD Pharma Strengthens Executive Team With Appointment Of Ana de Vera As Chief Medical Officer

NMD Pharma A/S, a clinical-stage biotechnology company focused on developing new and improved treatments for people living with neuromuscular diseases, has announced the appointment of Dr. Ana de Vera as Chief Medical Officer (CMO), effective immediately. With more than 20 years of experience in drug development and commercialization, Dr. de Vera has successfully led projects and development teams across a wide range of therapeutic areas and stages, including neuromuscular diseases.

In her new role, Dr. de Vera will oversee the continued development of NMD Pharma’s pipeline, with a particular focus on the company’s three ongoing Phase 2 clinical trials of NMD670. NMD670 is an orally bioavailable, skeletal muscle-specific chloride ion channel (ClC-1) inhibitor being evaluated in patients with generalized myasthenia gravis, spinal muscular atrophy, and Charcot-Marie-Tooth disease.

Prior to joining NMD Pharma, Dr. de Vera was Head of Development and Deputy CMO at Santhera Pharmaceuticals. There, she played a critical role in completing successful new drug applications and marketing authorization applications for AGAMREE® (vamorolone), a treatment for Duchenne muscular dystrophy, in both the United States and Europe. Under her leadership, regulatory applications were also extended to additional geographies, including the UK, Switzerland, China, Canada, and Israel. Beyond regulatory work, she provided strategic scientific guidance to commercial, market access, and medical affairs teams, helping ensure successful reimbursement and launch strategies.

Dr. Ana de Vera, newly appointed Chief Medical Officer at NMD Pharma, said in a statement, “Joining NMD Pharma represents an incredible opportunity to advance treatments for people living with neuromuscular diseases, many of which can significantly impact quality of life. Having led programs from early clinical development through to regulatory approval and commercialization, I am particularly excited about the potential of NMD670, the Company’s lead skeletal muscle specific ClC-1 inhibitor, to go beyond symptom management and directly improve muscle function. Together with the team, I am looking forward to supporting the development of this promising therapy for patients.”

Thomas Holm Pedersen, Chief Executive Officer of NMD Pharma, also added, “Dr. de Vera’s appointment represents the perfect alignment of expertise and vision to support NMD Pharma's future. Her deep understanding of neuromuscular diseases, coupled with her proven success in bringing innovative treatments to market, makes her an ideal leader for our clinical programs. As we progress our Phase 2 trials and prepare for the next stages of development, Dr. de Vera’s strategic insights and regulatory expertise will be crucial in realizing the full potential of our first-in-class ClC-1 inhibitor approach to improve quality of life for people living with serious neuromuscular disorders.”

Earlier in her career, Dr. de Vera spent over 15 years at Novartis AG in senior leadership positions, including Global Program Medical Director. In this capacity, she managed development programs in dermatology, neurology, immunology, and neuromuscular diseases. Her work included overseeing early clinical trials of bimagrumab, a monoclonal antibody developed to address muscle loss and weakness in sarcopenia, and supporting regulatory planning for inclusion body myositis, a rare neuromuscular condition.

Dr. de Vera is a certified neurologist in both Spain and Switzerland. She earned her medical degree from Oviedo University and has more than a decade of hands-on clinical experience in neurology. She has served as a visiting neurologist at several leading centers, including the Neurology Outpatient Clinic at University Hospital Basel and the Multiple Sclerosis Unit at Vall d’Hebron University Hospital, among others.